Presentation,
22nd annual San Antonio Breast Cancer Symposium
(Source: Breast Cancer Update for Surgeons, Program 1 2000)
Play
Audio Below:
We
know that prophylactic mastectomy substantially reduces breast cancer
risk. And, if you look in the moderate risk group – which was
defined by that very same Gail model, which is where these atypical
patients would fit – you can see that by prophylactic mastectomy
you reduce the incidence of breast cancer by 90 percent. We virtually
never suggest prophylactic mastectomy to someone with atypical hyperplasia
unless they have multiple other risk factors.
So,
for those young women with risks over five years of one or two percent,
close clinical follow-up is a perfectly appropriate option for the
early detection of breast cancer. However, for women who find their
level of risk unacceptable, we have clear-cut data that tamoxifen
provides benefits in atypical hyperplasia above and beyond those
seen in the high-risk population at large.
Chemoprevention
of breast cancer [Review]. Brown, P. H. and Lippman, S. M. (Reprint available from: Lippman
SM Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent 1515
Holcombe Blvd,Box 236 Houston, TX 77030 USA). Breast Cancer Research
& Treatment. 62(1):1-17, 2000 Jul.
Vitamin
A analogue for breast cancer prevention: a grade of F or incomplete?
Response Piantadosi, S. (Reprint available from: Piantadosi S Johns Hopkins
Univ, Sch Med, Johns Hopkins Oncol Ctr 550 N Broadway,Suite 1103
Baltimore, MD 21205 USA).. Journal of the National Cancer Institute.
92(3):274-275, 2000 Feb 2. No abstract
Tamoxifen
for the prevention of breast cancer in the high-risk woman.
Morrow, M. and Jordan, V. C. (Reprint available from: Morrow M 676
N St Clair St,13th Floor, Room 13-104 Chicago, IL 60611 USA).. Annals
of Surgical Oncology. 7(1):67-71, 2000 Jan-Feb. No abstract
